H.R. 10678: Fight Against Fentanyl Act
This bill would change the rules for a federal grant program called Byrne JAG, which gives money to state and local governments for criminal justice and public safety purposes.
What changes
The bill would let Byrne JAG funds be used not only for general law enforcement and justice-related activities, but also specifically for buying:
- fentanyl testing kits, and
- opioid reversal agents, such as naloxone products used to help treat opioid overdoses.
Practical effect
In plain terms, the bill would make it easier for police departments, sheriffs’ offices, and other eligible public agencies to use existing grant money to purchase tools that can identify fentanyl and respond to opioid overdoses. It does not create a new grant program or require spending; it simply expands the list of allowed uses for an existing one.
Relevant Companies
- MDT — Medtronic, which makes some medical products that could be used in emergency and overdose-response settings.
- PFE — Pfizer, which has pharmaceutical products and could be indirectly affected through opioid reversal agent demand depending on specific procurement choices.
- ENDP — Endo International, which has been associated with naloxone products in the past; any direct impact would depend on market availability and contract sourcing.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
4 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Oct. 01, 2026 | Introduced in House |
| Oct. 01, 2026 | Referred to the House Committee on the Judiciary. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
